High performance computing has entered a new phase, one where the chips inside a machine can reshape themselves around the code they are running. Instead of simply stacking more processors and drawing ...
Adaptive Biotechnologies Corporation announced that its clonoSEQ® test for measurable residual disease (MRD) will be prominently featured in 30 presentations at the upcoming American Society of ...
Adaptive test is starting to gain traction for high-performance computing and AI chips as test programs that rely on static limits and fixed test sequences reach their practical limits. The growing ...
Adaptive Biotechnologies Corporation is rated Hold as MRD segment momentum offset by competitive & valuation concerns. Read ...
Adaptive Biotechnologies Corporation announced that as of January 1, 2025, the new Medicare Clinical Laboratory Fee Schedule includes a payment rate of $2,007 for its clonoSEQ test used for assessing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback